| answer text |
<p>In negotiations with India, as with all our trading partners, the UK’s approach
to intellectual property (IP) is to strike a balance between rewarding research, innovation
and creativity, which can benefit all countries, whilst ensuring that medicines remain
affordable and reflecting wider public interests, such as access to and use of IP
on reasonable terms.</p><p> </p><p>The UK considers the TRIPS Agreement as an essential
tool to achieve this balance, including our support for flexibilities enshrined in
the Agreement.</p>
|
 |
